Extracellular vesicles: emerging therapeutic agents for liver fibrosis
Extracellular Vesicles and Circulating Nucleic Acids,
Год журнала:
2025,
Номер
6(2), С. 216 - 44
Опубликована: Май 7, 2025
Liver
fibrosis
is
a
progressive
condition
characterized
by
excessive
scar
tissue
buildup,
leading
to
impaired
liver
function
and
potentially
cirrhosis.
Despite
advancements
in
treatment
strategies,
effective
anti-fibrotic
therapies
remain
an
urgent
unmet
need.
Recent
research
has
identified
extracellular
vesicles
(EVs)
as
promising
therapeutic
agents
due
their
ability
mediate
intercellular
communication
regulate
key
fibrotic
pathways.
This
review
aims
provide
comprehensive
overview
of
the
potential
EVs
different
vitro
vivo
models
hepatic
fibrosis,
focusing
on
natural
effects
recent
engineering
for
enhanced
efficacy.
can
be
derived
from
various
cellular
sources,
including
mesenchymal
stromal
cells
(MSCs)
liver-resident
cells.
Biological
materials,
serum,
breast
milk,
bacteria,
plants,
also
serve
EV
sources.
Among
these,
MSC-EVs
stand
out
potential,
which
significantly
through
preconditioning
with
inflammatory
signals,
pharmacological
agents,
or
genetic
improve
quality
Engineering
techniques
have
further
expanded
applications,
enabling
use
precise
drug-delivery
vehicles.
Approaches
such
loading
compounds,
designing
customized
EVs,
creating
EV-liposome
hybrids
enable
targeted
delivery
activated
stellate
(HSCs),
central
drivers
progression.
These
strategies
enhance
efficacy
EV-based
treatments.
Both
engineered
critical
pathways
development,
activation
HSCs,
modulation
pro-fibrotic
genes,
matrix
deposition,
programmed
cell
death.
Additionally,
modulate
immune
responses,
fostering
microenvironment
conducive
repair
regeneration.
Combining
regenerative
properties
innovative
provides
highly
targeted,
approaches
restore
address
need
chronic
disease
therapies.
Язык: Английский
Therapeutic Potential of Umbilical Cord MSC-Derived Exosomes in a Severe Dry Eye Rat Model: Enhancing Corneal Protection and Modulating Inflammation
Sze-Min Chan,
Chris Tsai,
Tai-Ping Lee
и другие.
Biomedicines,
Год журнала:
2025,
Номер
13(5), С. 1174 - 1174
Опубликована: Май 11, 2025
Background/Objectives:
Dry
eye
disease
(DED)
is
a
multifactorial
inflammatory
that
disrupts
the
ocular
surface,
causing
tear
film
instability,
epithelial
damage,
and
chronic
inflammation.
Mesenchymal
stem
cell-derived
exosomes
(MSC-exos)
are
promising
therapeutics
with
immunomodulatory
regenerative
properties.
This
study
investigates
therapeutic
effects
of
umbilical
cord
MSC-derived
(UCMSC-exos)
in
severe
dry
model,
induced
by
surgical
resection
infra-orbital
(ILG)
extra-orbital
lacrimal
gland
(ELG)
rats.
Methods:
Clinical
evaluations,
including
volume
measurement,
slit
lamp
biomicroscopy,
fluorescein
staining,
spectral
domain
optical
coherence
tomography
(SD-OCT),
were
performed
to
assess
corneal
neovascularization,
abrasion,
epithelial/stromal
thickness.
Histopathological
analysis,
immunohistochemistry,
mRNA
gene
expression
conducted
evaluate
tissue
changes
marker
expression.
Results:
The
results
show
treatment
group
exhibited
significantly
reduced
neovascularization
compared
control
(p
=
0.030).
During
first
month,
Exo
also
had
lower
staining
area
0.032),
suggesting
accelerated
wound
healing.
SD-OCT
analysis
revealed
thickness
was
closer
normal
levels
0.02
p
0.006,
respectively).
UCMSC-exos
modulated
α-SMA
apoptosis
cornea.
Additionally,
cytokines
(IL-1β
TNF-α)
downregulated.
Conclusions:
These
findings
suggest
MSC-exosome
therapy
offers
novel,
cell-free
approach
for
managing
DED,
modulating
response.
Язык: Английский